Shares Of Cytomedix Inc. (CMXI) Rallies in the Mid-Day Trading Session
The stock of Cytomedix Inc. (OTC: CMXI) is soaring in the mid-day trading session. The stock is trading 4.12% higher today on an announcement of a Proposed National Coverage Determination Memo by CMS for Autologous PRP Gel in Chronic Wound Care. At present, the penny stock is trading at $1.77 with 1.5 million shares traded, compared to Wednesday’s close of $1.70.
Today, the company announced that the proposed National Coverage Determination (NCD) memo by the Centers for Medicare & Medicaid Services (CMS) for autologous blood-derived products for chronic non-healing wounds bodes well for the company. The company said that in its decision memo CMS proposed coverage through its Coverage with Evidence Development (CED) program for all three major wound categories; diabetic, venous and pressure wounds.
The stock has made a significant gain of 21% in the last ten trading sessions. The stock made a significant gain of 112% in the last six months. With market capitalization of $166.35 million, CMXI’s 52-week high is $1.97 and 52- week low is $0.27.
- Check out all our other hot penny stocks: Hot Stocks
- This newsletter has been helping traders make a killing on CMXI. Click here for a 25% discount offer.
- See today’s top stock picks and market analysis
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage Want more?
- Check out the message board buzz for CMXI
- See what newsletters are recommending this stock pick
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Tech24.org is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.